Table 5. Estimated time from HIV seroconversion to antiretroviral treatment initiation and delay in antiretroviral treatment initiation, Cameroon, 2007–2010.
| Year of ART initiation | Time from HIV seroconversion to ART initiation |
Delay in ART initiationa (95% CI) | |
|---|---|---|---|
| Mean years (95% CI) | Median years (IQR) | ||
| 2007–2009 | |||
| All | 10.4 (10.3 to 10.5) | 9.9 (7.6 to 13.1) | 3.4 (3.1 to 3.7) |
| Women | 10.2 (10.0 to 10.3) | 9.7 (7.5 to 12.7) | 3.2 (2.8 to 3.7) |
| Men | 10.9 (10.6 to 11.1) | 10.6 (7.9 to 13.8) | 3.9 (3.5 to 4.3) |
| 2010 | |||
| All | 9.8 (9.6 to 10.0) | 9.2 (6.6 to 12.7) | 5.8 (5.6 to 6.2) |
| Women | 9.7 (9.4 to 10.0) | 9.1 (6.6 to 12.6) | 5.6 (5.2 to 6.0) |
| Men | 10.0 (9.6 to 10.5) | 9.4 (6.8 to 12.9) | 6.0 (5.4 to 6.6) |
ART: antiretroviral therapy; CI: confidence interval; HIV: human immunodeficiency virus; IQR: interquartile range.
a The delay in ART initiation was calculated by subtracting the average time from seroconversion to ART eligibility from the average time between HIV seroconversion and ART initiation.
Note: The ART eligibility threshold was 200 cells/μL in 2007–2009 and 350 cells/μL in 2010.